Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE).

Avecilla ST, Goss C, Marionneaux SM, Wright DR, Leiva TD, Tonon JA, Smith KM, Maslak P.

Adv Cell Gene Ther. 2018 Sep;1(2). pii: e15. doi: 10.1002/acg2.15. Epub 2018 Aug 13.

2.

Evaluation of peripheral blood mononuclear cell collection by leukapheresis.

Chen J, Goss C, Avecilla ST, Hong H, Walsh E, Wuest D, Maslak P, Pessin MS.

Transfusion. 2019 May;59(5):1765-1772. doi: 10.1111/trf.15186. Epub 2019 Feb 12.

PMID:
30747437
3.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

4.

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M.

N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.

5.

Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma.

Royston DJ, Gao Q, Nguyen N, Maslak P, Dogan A, Roshal M.

Am J Clin Pathol. 2016 Jul;146(1):41-9. doi: 10.1093/ajcp/aqw052.

6.

Comparison of manual hematocrit determinations versus automated methods for hematopoietic progenitor cell apheresis products.

Avecilla ST, Marionneaux SM, Leiva TD, Tonon JA, Chan VT, Moung C, Meagher RC, Maslak P.

Transfusion. 2016 Feb;56(2):528-32. doi: 10.1111/trf.13346. Epub 2015 Sep 23.

7.

Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections.

Peerschke EI, Moung C, Pessin MS, Maslak P.

Transfusion. 2015 Aug;55(8):2001-9. doi: 10.1111/trf.13078. Epub 2015 Mar 21.

8.

Using the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer.

Peerschke EI, Pessin MS, Maslak P.

Am J Clin Pathol. 2014 Oct;142(4):506-12. doi: 10.1309/AJCPCVZ5B0BOYJGN.

9.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

10.

Morphologic identification of atypical chronic lymphocytic leukemia by digital microscopy.

Marionneaux S, Maslak P, Keohane EM.

Int J Lab Hematol. 2014 Aug;36(4):459-64. doi: 10.1111/ijlh.12167. Epub 2013 Nov 25.

PMID:
24400650
11.

Comparison of automated platelet counts and potential effect on transfusion decisions in cancer patients.

Marionneaux S, Francisco N, Chan V, Hanenberg J, Rafael J, Chua C, Jia R, Yao J, Lynch J, Chan V, Maslak P.

Am J Clin Pathol. 2013 Nov;140(5):747-54. doi: 10.1309/AJCP58INTITVGQZI.

PMID:
24124156
12.

A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.

Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, Zhang J, Wei L, Wu G, Rusch M, Nagahawatte P, Ma J, Chen SC, Song G, Cheng J, Meyers P, Bhojwani D, Jhanwar S, Maslak P, Fleisher M, Littman J, Offit L, Rau-Murthy R, Fleischut MH, Corines M, Murali R, Gao X, Manschreck C, Kitzing T, Murty VV, Raimondi S, Kuiper RP, Simons A, Schiffman JD, Onel K, Plon SE, Wheeler D, Ritter D, Ziegler DS, Tucker K, Sutton R, Chenevix-Trench G, Li J, Huntsman DG, Hansford S, Senz J, Walsh T, Lee M, Hahn CN, Roberts K, King MC, Lo SM, Levine RL, Viale A, Socci ND, Nathanson KL, Scott HS, Daly M, Lipkin SM, Lowe SW, Downing JR, Altshuler D, Sandlund JT, Horwitz MS, Mullighan CG, Offit K.

Nat Genet. 2013 Oct;45(10):1226-1231. doi: 10.1038/ng.2754. Epub 2013 Sep 8.

13.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

14.

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA.

Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.

15.

Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial.

Lamanna N, Heffner LT, Kalaycio M, Schiller G, Coutre S, Moore J, Seiter K, Maslak P, Panageas K, Golde D, Weiss MA.

Cancer. 2013 Mar 15;119(6):1186-94. doi: 10.1002/cncr.27901. Epub 2012 Dec 20.

16.

Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia.

Baljevic M, Abdel-Wahab O, Rampal R, Maslak PG, Klimek VM, Rosenblat TL, Douer D, Levine RL, Tallman MS.

Acta Haematol. 2013;129(1):48-54. doi: 10.1159/000342493. Epub 2012 Nov 7.

PMID:
23147462
17.

Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.

Diab A, Zickl L, Abdel-Wahab O, Jhanwar S, Gulam MA, Panageas KS, Patel JP, Jurcic J, Maslak P, Paietta E, Mangan JK, Carroll M, Fernandez HF, Teruya-Feldstein J, Luger SM, Douer D, Litzow MR, Lazarus HM, Rowe JM, Levine RL, Tallman MS.

Leuk Res. 2013 Jan;37(1):32-6. doi: 10.1016/j.leukres.2012.08.025. Epub 2012 Oct 24.

18.

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.

Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

19.

Acute myeloid leukemia.

O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Mar;9(3):280-317. No abstract available.

PMID:
21393440
20.

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, Li H, Tyson L, Scheinberg DA.

Cancer Immunol Immunother. 2010 Oct;59(10):1467-79. doi: 10.1007/s00262-010-0871-8. Epub 2010 Jun 8.

21.

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA.

Blood. 2010 Jul 15;116(2):171-9. doi: 10.1182/blood-2009-10-250993. Epub 2010 Apr 16.

22.

Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy.

Frattini MG, Maslak PG.

J Natl Compr Canc Netw. 2008 Nov;6(10):995-1002. Review.

PMID:
19176197
23.

Acute myeloid leukemia.

O'Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG, Millenson M, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stone RM, Tallman MS, Wang E, White FL.

J Natl Compr Canc Netw. 2008 Nov;6(10):962-93. Review. No abstract available.

PMID:
19176196
24.

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA, Zelenetz AD, Weiss MA.

J Clin Oncol. 2009 Feb 1;27(4):491-7. doi: 10.1200/JCO.2008.16.4459. Epub 2008 Dec 15.

25.

Azacitidine and the beginnings of therapeutic epigenetic modulation.

O'Dwyer K, Maslak P.

Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. doi: 10.1517/14656566.9.11.1981 . Review.

PMID:
18627335
26.

A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease.

Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, Zakhaleva V, Pinilla-Ibarz J, Berman E, Scheinberg DA.

Leukemia. 2008 Aug;22(8):1613-6. doi: 10.1038/leu.2008.7. Epub 2008 Feb 7. No abstract available.

PMID:
18256684
27.

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.

Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, Pandolfi PP, Nimer SD.

Clin Cancer Res. 2008 Feb 1;14(3):826-32. doi: 10.1158/1078-0432.CCR-07-0318.

28.

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.

Zhou P, Comenzo RL, Olshen AB, Bonvini E, Koenig S, Maslak PG, Fleisher M, Hoffman J, Jhanwar S, Young JW, Nimer SD, Boruchov AM.

Blood. 2008 Apr 1;111(7):3403-6. doi: 10.1182/blood-2007-11-125526. Epub 2008 Jan 23.

29.

Myelodysplastic syndrome associated with isolated del (5q) chromosome abnormality ("5q- syndrome").

Maslak P.

Blood. 2007 Dec 1;110(12):3825. No abstract available.

PMID:
18062093
30.

Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55. Erratum in: Clin Cancer Res. 2007 Sep 1;13(17):5226.

31.

Histoplasmosis.

Maslak P, Southern L.

Blood. 2007 Apr 1;109(7):2677. No abstract available.

PMID:
17489105
32.

Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Apr 1;13(7):2023-9.

33.

Monoclonal antibody therapy of APL.

Maslak PG, Jurcic JG, Scheinberg DA.

Curr Top Microbiol Immunol. 2007;313:205-19. Review.

PMID:
17217045
34.

Acanthocytes.

Maslak P.

Blood. 2006 Sep 1;108(5):1433. No abstract available.

PMID:
16955552
35.

Grading follicular lymphomas in fine-needle aspiration biopsies: the role of ThinPrep slides and flow cytometry.

Brandao GD, Rose R, McKenzie S, Maslak P, Lin O.

Cancer. 2006 Oct 25;108(5):319-23.

36.

Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?

Portlock CS, O'Connor OA, Straus DJ, Rosenzweig L, Dumitrescu O, Lin O, Maslak P.

Leuk Lymphoma. 2006 Jul;47(7):1260-4.

PMID:
16923555
37.

Antibody-drug conjugates in acute myeloid leukemia.

Scheinberg DA, Jurcic JG, Maslak P.

Nat Clin Pract Oncol. 2006 May;3(5):238-9. No abstract available.

PMID:
16682998
38.

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA.

J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6.

PMID:
16520464
39.

Acute myeloid leukemia clinical practice guidelines in oncology.

O'Donnell MR, Appelbaum FR, Baer MR, Byrd JC, Coutre SE, Damon LE, Erba HP, Estey E, Foran J, Lancet J, Maness LJ, Maslak PG, Millenson M, Moore JO, Przepiorka D, Shami P, Smith BD, Stone RM, Tallman MS.

J Natl Compr Canc Netw. 2006 Jan;4(1):16-36. No abstract available.

PMID:
16403402
40.

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S.

Leukemia. 2006 Feb;20(2):212-7.

PMID:
16357841
41.

Therapy of acute promyelocytic leukemia.

Soignet S, Maslak P.

Adv Pharmacol. 2004;51:35-58. Review. No abstract available.

PMID:
15464904
42.

Chronic myelomonocytic leukemia.

Maslak P, McKenzie S.

Blood. 2003 Dec 1;102(12):3863. No abstract available.

PMID:
14666928
43.

Clinical applications of molecular monitoring in leukemia.

Maslak P.

Curr Hematol Rep. 2003 Jan;2(1):43-8. Review.

PMID:
12901153
44.

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D.

J Clin Oncol. 2003 Apr 1;21(7):1278-84.

PMID:
12663715
45.

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.

Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA.

Cancer. 2003 Feb 15;97(4):1025-32.

46.

Mast cell leukemia.

Maslak P.

Blood. 2003 Feb 1;101(3):789. No abstract available.

PMID:
12564414
47.

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.

Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE.

Cancer. 2002 Aug 1;95(3):581-7.

48.

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D.

J Clin Oncol. 2002 Apr 15;20(8):2157-70.

PMID:
11956278
49.

Synthesis, Structure, and Nucleophile-Induced Rearrangements of Spiroketones.

Maslak P, Varadarajan S, Burkey JD.

J Org Chem. 1999 Oct 29;64(22):8201-8209.

PMID:
11674737
50.

Acute myeloid leukemia with t(5;18)(q35;q21).

Wang ES, Maslak P, Cathcart K, Jurcic JG.

Cancer Genet Cytogenet. 2001 May;127(1):71-3.

PMID:
11408069

Supplemental Content

Loading ...
Support Center